Biomimetic platelet nanoparticles encapsulated with proteasome inhibitor bortezomib for multiple myeloma treatment
Source abstract
Abstract
The discovery of bortezomib (BTZ) has been a major clinical breakthrough for multiple myeloma (MM) treatment. However, its clinical application is restricted to a low tumor-targeting ability, fast clearance, and treatment-related toxicity. Here, we report a targeting strategy of MM by poly(lactic-co-glycolic acid)(PLGA) nanoparticles cloaking with platelet membranes (PMs) encapsulating BTZ (PM/BTZNPs). The drug delivery system could encapsulate sufficient BTZ with suitable nanoparticle characteristics for cellular uptake via an easy fabrication process. Of note, PM coating markedly enhances the selectivity, cellular uptake, and anticancer effects of BTZ in LP-1 cells. PM/BTZNPs further display a targeted drug delivery system to MM, causing a low toxicity effect and exhibiting an obvious survival advantage compared to nontargeted BTZ. Therefore, PM/BTZNPs, as a biomimetic nanotherapeutic formulation, demonstrate a high potential for MM patients.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Multiple Myeloma Research and Treatments · Dendrimers and Hyperbranched Polymers · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School 1 , Nanjing, China
Department of Rheumatology and Immunology, Institute of Translational Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School 2 , Nanjing, China
Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine 3 , Nanjing, China
Funding
Foundation for Innovative Research Groups of the National Natural Science Foundation of China
References (31)
Show source-provided references
1. Population screening for smoldering multiple myeloma reveals high prevalence
2. Development of blood components samples collection as a source for new biomarkers search in multiple myeloma10.1200/jco.2022.40.16_suppl.e15009 ↗
3. Evaluating serum-free light chain ratio as a biomarker for multiple myeloma10.1200/jco.2022.40.16_suppl.8047 ↗
4. Diagnosis and management of multiple myeloma: A review10.1001/jama.2022.0003 ↗
5. Multiple myeloma10.1016/s0140-6736(21)00135-5 ↗
6. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase III trial10.1200/jco.21.02734 ↗
7. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma10.1038/s41565-022-01310-1 ↗
8. Cancer-cell-biomimetic nanoparticles for targeted therapy of multiple myeloma based on bone marrow homing10.1002/adma.202107883 ↗
9. Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma10.1200/jco.2021.39.15_suppl.8024 ↗
10. CD44-specific A6 short peptide boosts targetability and anticancer efficacy of polymersomal epirubicin to orthotopic human multiple myeloma10.1002/adma.201904742 ↗
11. Daratumumab immunopolymersome-enabled safe and CD38-targeted chemotherapy and depletion of multiple myeloma10.1002/adma.202007787 ↗
12. BSA-AIE nanoparticles with boosted ROS generation for immunogenic cell death immunotherapy of multiple myeloma10.1002/adma.202208692 ↗
13. Apoptotic extracellular vesicles ameliorate multiple myeloma by restoring Fas-mediated apoptosis10.1021/acsnano.1c03517 ↗
14. Multidrug nanomedicine10.1038/s41565-022-01265-3 ↗
15. Metal–organic framework (MOF)-based drug/cargo delivery and cancer therapy10.1002/adma.201606134 ↗
16. Metal-organic frameworks for biomedical applications10.1002/smll.20190684 ↗
17. Engineered mesoporous silica-based nanoparticles as smart chemotherapy nanodevice for bortezomib administration10.1039/d2qm01009g ↗
18. Enhanced tumour penetration and prolonged circulation in blood of polyzwitterion–drug conjugates with cell-membrane affinity10.1038/s41551-021-00701-4 ↗
19. Targeting drugs to tumours using cell membrane-coated nanoparticles10.1038/s41571-022-00699-x ↗
20. Recent progress in targeted delivery vectors based on biomimetic nanoparticles10.1038/s41392-021-00631-2 ↗
21. Biomimetic nanoerythrosome-coated aptamer–DNA tetrahedron/maytansine conjugates: pH-responsive and targeted cytotoxicity for HER2-positive breast cancer10.1002/adma.202109609 ↗
22. Herpesvirus-mimicking DNAzyme-loaded nanoparticles as a mitochondrial DNA stress inducer to activate innate immunity for tumor therapy10.1002/adma.202204585 ↗
23. How circulating cancer cells disguise: The role of platelets10.1200/jco.2022.40.16_suppl.e15011 ↗
24. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance10.1016/j.ccell.2023.01.001 ↗
25. Targeted immunomodulation therapy for cardiac repair by platelet membrane engineering extracellular vesicles via hitching peripheral monocytes10.1016/j.biomaterials.2022.121529 ↗
26. Nanoparticle biointerfacing by platelet membrane cloaking10.1038/nature15373 ↗
27. A platelet intelligent vehicle with navigation for cancer photothermal-chemotherapy10.1021/acsnano.2c00453 ↗
28. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors10.1038/s41467-021-22311-z ↗
29. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications10.7150/thno.47841 ↗
30. Erythrocyte–platelet hybrid membrane coating for enhanced nanoparticle functionalization10.1002/adma.201606209 ↗
31. A6 peptide-tagged core-disulfide-cross-linked micelles for targeted delivery of proteasome inhibitor carfilzomib to multiple myeloma in vivo10.1021/acs.biomac.9b01790 ↗